The study by researchers from ICMR & Bharat Biotech presents interim results from phase 2 trial, along with analysis from 3-month follow-up of phase 1 trial participants.
Bharat Biotech's phase-3 trial was conducted on 25,800 participants between 18-98 years of age, including 2,433 over the age of 60 and 4,500 with comorbidities.
Over 10 crore people in two priority groups — above 60 years and those above 45 years with comorbidities — will be covered in the 2nd phase that began Monday.
Govt said Wednesday that those getting the Covid-19 vaccination at private hospitals will have to pay for it, setting the stage for their participation in immunisation drive.
Covaxin is one of two vaccines being administered as part of India’s Covid vaccination drive. It was given conditional emergency-use nod in absence of complete Phase 3 trial data.
Govt considers the 50+ category to be the 'biggest priority group' in the city, and the numbers are being included in the database on the basis of electoral roll figures.
Minutes from Jan meetings showed that India’s drug regulatory agency insisted on seeing efficacy data for Covaxin, before approving it for a restricted use in 'clinical trial mode'.
The claim that VB-GRAMG provides an employment guarantee is incorrect. The only guarantee is to 'empower' the Centre to allow partial implementation in notified areas alone.
It is argued that India-Israel ties are moving from buyer–seller dynamic to one focused on joint development & manufacturing partnership, a shift 'more durable' than traditional arms sales.
Don’t blame misfortune. This is colossal incompetence and insensitivity. So bad, heads would have rolled even in the old PSU-era Indian Airlines and Air India.
COMMENTS